PDCD1 and cholangiocarcinoma: Notably, this combination approach has yielded positive responses in individuals with late-stage renal cell carcinoma (RCC) and heavily treated cholangiocarcinoma (CCA) that were previously unresponsive to anti-PD-1 therapy.